| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Circulation. 2005;112:1806-1812.)
© 2005 American Heart Association, Inc.
Vascular Medicine |
From the Departments of Cardiovascular Medicine (A.O., K.N., H.F., T.I., K.K., K.M., D.M., K.F.K., T.O.), Brain Science (I.M., M.A.), and Thoracic and Cancer Surgery (H.D.), Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Division of Cardiology (H.M.), National Hospital Organization Okayama Medical Center, Okayama, Japan.
Correspondence to Aiko Ogawa, MD, Department of Cardiovascular Medicine, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, 2-5-1 Shikata-cho, Okayama 700-8558, Japan. E-mail aiko-oky{at}umin.ac.jp
Received January 14, 2005; revision received June 19, 2005; accepted July 1, 2005.
Background Idiopathic pulmonary arterial hypertension (IPAH) is associated with proliferation of smooth muscle cells (SMCs) in small pulmonary arteries. There is no therapy that specifically inhibits SMC proliferation. Recent studies reported that prednisolone (PSL) inhibits the postangioplasty proliferation of SMCs in atherosclerotic arteries. In this study, we tested the hypothesis that PSL has antiproliferative effects on pulmonary artery SMCs of patients with IPAH.
Methods and Results Pulmonary artery SMCs were harvested from the pulmonary arteries of 6 patients with IPAH who underwent lung transplantation. Control SMCs were obtained from 5 patients with bronchogenic carcinoma who underwent lung lobectomy. After incubation in the presence of platelet-derived growth factor (PDGF), PSL was added at different concentrations and cell proliferation was assessed by 3H-thymidine incorporation. PSL (2x104 and 2x103 mol/L) significantly inhibited PDGF-stimulated proliferation (P<0.05) of SMCs from patients with IPAH but did not affect cell viability of SMCs, as confirmed by trypan blue staining. In cell cycle analysis using a microscope-based multiparameter laser scanning cytometer, PSL inhibited the progression of SMCs from G0/G1 to the S phase. This inhibition was associated with increased p27 expression level. PSL (2x104 mol/L) also inhibited PDGF-induced SMC migration.
Conclusions Our results indicate that PSL has an antiproliferative effect on cultured SMCs of pulmonary arteries from patients with IPAH and suggest that PSL may be potentially useful therapeutically in patients with IPAH.
Key Words: prednisolone myocytes hypertension, pulmonary muscle, smooth
This article has been cited by other articles:
![]() |
A. Ogawa, A. L. Firth, W. Yao, L. J. Rubin, and J. X.-J. Yuan Prednisolone inhibits PDGF-induced nuclear translocation of NF-{kappa}B in human pulmonary artery smooth muscle cells Am J Physiol Lung Cell Mol Physiol, October 1, 2008; 295(4): L648 - L657. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Zhang, H. Dong, L. J. Rubin, and J. X.-J. Yuan Upregulation of Na+/Ca2+ exchanger contributes to the enhanced Ca2+ entry in pulmonary artery smooth muscle cells from patients with idiopathic pulmonary arterial hypertension Am J Physiol Cell Physiol, June 1, 2007; 292(6): C2297 - C2305. [Abstract] [Full Text] [PDF] |
||||
|
Circulation Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2005 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |